Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06149286 · ClinicalTrials.gov registry record · Phase 3

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

A Phase 3 study of Relapsed/Refractory Follicular Lymphoma and Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL), sponsored by Regeneron Pharmaceuticals.

Recruiting
Registry status
Phase 3
Development phase
470
Enrollment target
20
Study locations

NCT06149286 is a Phase 3 study of Relapsed/Refractory Follicular Lymphoma and Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 470 participants, below the 541-participant average among 3 other Relapsed/Refractory Follicular Lymphoma trials with a reported enrollment target (13% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06149286, a Phase 3 study of Relapsed/Refractory Follicular Lymphoma and Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.

RECRUITING
Registry status
Phase 3
Development phase
470 participants
Enrollment target
20
Study locations

Study Summary

This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called "relapsed"), or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL). This study will be made up of two parts (Part 1 not randomized, Part 2 randomized - controlled). The aim of Part 1 of the study is to see how safe and tolerable the study drug is when used in combination with lenalidomide, in participants with FL or MZL, and to determine the dose of the study drug to be used in Part 2 of this study. This combination is considered "first-in-human" as it has not been tested as a combination treatment in humans before. The aim of Part 2, of the study is to assess how well the combination of the study drug and lenalidomide works compared to the combination of rituximab (called "the comparator drug") and lenalidomide. The combination of comparator drug and lenalidomide is the current standard-of-care treatment for relapsed/refractory FL and/or MZL. Standard-of-care means the usual medication expected and used when receiving treatment for a condition. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug in combination with lenalidomide * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects) * The impact from the study drug on quality-of-life and ability to complete routine daily activities

Conditions Studied

Relapsed/Refractory Follicular Lymphoma Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

Interventions

  • DRUG Rituximab
  • DRUG Lenalidomide
  • DRUG Odronextamab

Study Locations (20)

New York

  • Stony Brook University Hospital - Stony Brook
  • Clinical Research Alliance Inc - Westbury

New South Wales

  • Liverpool Hospital - Liverpool
  • Calvary Mater Newcastle - Waratah

Other

  • Medical University Vienna - Vienna
  • Klinikum Wels-Grieskirchen - Wels

California

  • David Geffen School of Medicine at UCLA - Los Angeles

Florida

  • Boca Raton Clinical Research (BRCR) Global - Plantation

Indiana

  • Indiana University and Comprehensive Cancer Center - Indianapolis

Mississippi

  • Hattiesburg Clinic - Hattiesburg

New Hampshire

  • Dartmouth Cancer Center - Lebanon

Trial Details

FieldValue
Enrollment Target 470 participants
Start Date 2023-12-28
Est. Completion 2029-01-23
Phase Phase 3

Sponsor

Regeneron Pharmaceuticals

280 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06149286

The ClinicalTrials.gov registry entry for NCT06149286 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 470 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 541-participant average among 3 other Relapsed/Refractory Follicular Lymphoma trials with a reported enrollment target (13% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Relapsed/Refractory Follicular Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Rituximab is the first listed.

NCT06149286 reports 20 study locations spanning 17 distinct geographic areas - top geographies include New York, New South Wales, Other.

Frequently Asked Questions

What is clinical trial NCT06149286 about?

NCT06149286 is a clinical study titled "A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma". This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (cal...

What is the current status of trial NCT06149286?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 470 participants. The study started on 2023-12-28. Estimated completion is 2029-01-23.

What conditions does trial NCT06149286 study?

This clinical trial studies the following conditions: Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL).

What interventions are being tested in trial NCT06149286?

The interventions under investigation include: Rituximab (DRUG), Lenalidomide (DRUG), Odronextamab (DRUG).

Who is sponsoring clinical trial NCT06149286?

This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06149286 being conducted?

This trial has 20 study locations across California, Florida, Indiana, Mississippi, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsed/Refractory Follicular Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Relapsed/Refractory Follicular Lymphoma

All registered trials for this condition

Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.